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Phosphorylation and Stabilization of 
PIN1 by JNK Promote Intrahepatic 
Cholangiocarcinoma Growth
Alessio Lepore,1* Pui Man Choy,2* Nathan C.W. Lee,1 Maria Annunziata Carella,3 Rosy Favicchio,4 Marco A. Briones- Orta,2,5 
Shannon S. Glaser,6 Gianfranco Alpini ,7 Clive D’Santos,8 Reuben M. Tooze,1 Mihaela Lorger,1 Wing- Kin Syn,2,9-11 
Athanasios Papakyriakou ,12 Georgios Giamas ,13 Concetta Bubici ,3** and Salvatore Papa 1,2**
BaCKgRoUND aND aIMS: Intrahepatic cholangiocar-
cinoma (ICC) is a highly aggressive type of liver cancer 
in urgent need of treatment options. Aberrant activation 
of the c- Jun N- terminal kinase ( JNK) pathway is a key 
feature in ICC and an attractive candidate target for its 
treatment. However, the mechanisms by which constitutive 
JNK activation promotes ICC growth, and therefore the 
key downstream effectors of this pathway, remain unknown 
for their applicability as therapeutic targets. Our aim was 
to obtain a better mechanistic understanding of the role 
of JNK signaling in ICC that could open up therapeutic 
opportunities.
appRoaCH aND ReSUltS: Using loss- of- function and 
gain- of- function studies in vitro and in vivo, we show that 
activation of the JNK pathway promotes ICC cell prolifera-
tion by affecting the protein stability of peptidyl- prolyl cis- 
trans isomerase NIMA- interacting 1 (PIN1), a key driver 
of tumorigenesis. PIN1 is highly expressed in ICC primary 
tumors, and its expression positively correlates with active 
JNK. Mechanistically, the JNK kinases directly bind to and 
phosphorylate PIN1 at Ser115, and this phosphorylation 
prevents PIN1 mono- ubiquitination at Lys117 and its pro-
teasomal degradation. Moreover, pharmacological inhibition 
of PIN1 through all- trans retinoic acid, a Food and Drug 
Administration– approved drug, impairs the growth of both 
cultured and xenografted ICC cells.
CoNClUSIoNS: Our findings implicate the JNK- PIN1 
regulatory axis as a functionally important determinant for 
ICC growth, and provide a rationale for therapeutic target-
ing of JNK activation through PIN1 inhibition. (Hepatology 
2021;74:2561-2579).
Intrahepatic cholangiocarcinoma (ICC) is a tumor of the bile ducts within the liver that arises pri-marily from an uncontrolled proliferation of 
transformed cholangiocytes. With a global increas-
ing incidence and mortality rates, ICC represents 
the second- most- frequent primary liver tumor after 
HCC.(1- 3) Currently, there are no curative chemo-
therapies for ICC, and efforts to develop molecular- 
targeted therapies have been limited due to the lack 
of a detailed understanding of the molecular mecha-
nisms underlying the disease.(2)
ICC usually develops in the context of both chronic 
inflammation of the biliary tract and liver injury 
that foster the accumulation of genetic mutations 
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in proto- oncogenes and tumor suppressors, such as 
KRAS and p53, which in turn lead to the constitu-
tive activation of signaling pathways involved in cell 
proliferation.(4- 7) One of the major signaling pathways 
that are activated by mutant KRAS in ICC models 
is the c- Jun N- terminal kinase ( JNK) signaling,(8) 
a member of the mitogen- activated protein kinase 
(MAPK) family.(9- 11) Activation of JNK signaling 
facilitates the development of ICC by promoting the 
hyperproliferation of transformed bile duct cells.(8) 
Although the pharmacologic inhibition of the JNK 
kinase activity impairs the development of ICC in 
several mouse models of liver injury,(8) active JNK is 
a challenging protein to target, due to its physiolog-
ical and cell type– specific functions in the liver.(12- 15) 
Therefore, we sought to obtain a better understand-
ing of the mechanisms by which active JNK signal-
ing promotes ICC, because the identification of the 
major downstream effectors of the JNK/MAPK path-
way could lead to the development of much- needed 
molecular- targeted therapeutics.
A key downstream effector of the oncogenic KRAS 
signal is PIN1, an evolutionarily conserved peptidyl- 
prolyl cis- trans isomerase (PPIase). PIN1 catalyzes 
the cis- trans isomerization of peptidyl- prolyl bonds 
in phosphorylated Ser/Thr- Pro motifs of the target 
proteins.(16- 21) Through its PPIase activity, PIN1 
affects the function of a large and diverse array of 
phosphorylated target proteins, including oncopro-
teins and tumor suppressors.(18- 24) PIN1 is frequently 
highly expressed in human cancers, and its expres-
sion correlates with poor patient prognosis.(20,24) For 
instance, PIN1 is overexpressed in invasive ductal 
carcinoma breast cancer, and cooperates with acti-
vated JNK and oncogenic RAS in promoting deregu-
lated cell proliferation by increasing the expression of 
the cell cycle regulator cyclin D1.(16,17,24) PIN1 also 
cooperates with oncogenic KRAS in driving cellular 
transformation in pancreatic ductal adenocarcinoma 
(PDAC) and is required for PDAC cell viability.(21) 
Given that ICC is driven by mutant KRAS and active 
JNK,(4,5,8) and that a proportion of invasive ductal 
carcinoma breast cancer and PDAC share an inflam-
matory origin with ICC,(8,25,26) an interesting ques-
tion is whether PIN1 plays a role in ICC. However, 
because genetic and/or genomic studies to date have 
rarely found mutations and amplifications of the 
PIN1 gene,(24) the molecular mechanisms underlying 
© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is 
an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.31983
Potential conflict of interest: Nothing to report.
aRtICle INFoRMatIoN:
From the 1 Leeds Institute of Medical Research at St. James’,  Faculty of Medicine and Health,  University of Leeds,  St. James’ University 
Hospital, Leeds, United Kingdom; 2 Institute of Hepatology,  Foundation for Liver Research and Birkbeck University of London, London, 
United Kingdom; 3 Center for Genome Engineering and Maintenance,  Department of Life Sciences,  College of Health, Medicine 
and Life Sciences,  Brunel University London, Uxbridge, United Kingdom; 4 Department of Surgery and Cancer,  Imperial College, 
London, United Kingdom; 5 Department of Infectious Disease,  Imperial College, London, United Kingdom; 6 Department of Medical 
Physiology,  Texas A&M University, Bryan, TX; 7 Division of Gastroenterology,  Department of Medicine,  Richard L. Roudebush VA 
Medical Center,  Indiana University, Indianapolis, IN; 8 Cancer Research UK Cambridge Institute,  University of Cambridge, Cambridge, 
United Kingdom; 9 Section of Gastroenterology,  Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC; 10 Division of 
Gastroenterology and Hepatology,  Department of Medicine,  Medical University of South Carolina, Charleston, SC; 11 Department of 
Physiology,  Faculty of Medicine and Nursing,  University of Basque Country UPV/EHU, Leioa, Spain; 12 Institute of Biosciences and 
Applications,  National Center for Scientific Research, Athens, Greece; 13 Department of Biochemistry and Biomedicine,  School of Life 
Sciences,  University of Sussex, Brighton, United Kingdom.
aDDReSS CoRReSpoNDeNCe aND RepRINt ReQUeStS to:
Salvatore Papa, Ph.D.  
St. James’ University Hospital  
Beckett Street, Wellcome Trust Brenner Building, 6.14  
Leeds LS9 7TF, United Kingdom  
E- mail: s.papa@leeds.ac.uk  
Tel.: +44- 113- 343- 9038 
Hepatology, Vol. 74, No. 5, 2021 LEPORE, CHOY, ET AL.
2563
PIN1 overexpression need to be understood at the 
cell signaling level.
Here we demonstrate that the constitutive activa-
tion of JNK leads to elevated levels of PIN1 expres-
sion, thus promoting ICC cell proliferation. We 
show that JNK proteins directly interact with and 
phosphorylate PIN1 at Ser115. The phosphoryla-
tion of PIN1 at this specific residue directly causes 
the increase in intracellular PIN1 levels by preventing 
its mono- ubiquitination at Lys117, and, consequently, 
inhibiting its proteasomal degradation. We also show 
the potential application of PIN1 inhibition using all- 
trans retinoic acid (ATRA)(27) for ICC therapy.
Materials and Methods
tISSUe MICRoaRRayS aND 
IMMUNoHIStoCHeMIStRy
Formalin fixed paraffin- embedded human ICC used 
in tissue microarrays (TMAs) were purchased from 
Pantomics (tissue block LVC1261), consisting of 42 
cases, 126 cores, and one normal adjacent nontumor liver 
tissue core paired with two tumor tissue cores from each 
patient. Immunohistochemistry staining of sequential 
sections was carried out using a two- step protocol. After 
antigen retrieval, each TMA slide, consisting of serial 
tissue cuts, was incubated with validated anti- human 
PIN1 antibody (1:50; H123; Santa Cruz Biotechnology, 
Inc., Dallas, TX)(28) and anti- human phospho(p)- JNK 
(1:50; 9251; Cell Signaling Technology).(29,30) The 
quantification of PIN1 and phosphorylated JNK (p- 
JNK) staining was evaluated by randomly choosing five 
non- overlapping fields at ×40 for each core and quan-
tified by counting the number of PIN1(+) or p- JNK(+) 
biliary epithelial cells/field and dividing by the total 
number of biliary epithelial cells per field.
XeNogRaFt tUMoR MoDelS
For xenograft experiments, 3 × 106 CCLP1 parental 
or nonspecific short hairpin RNA (shNS)– expressing, 
JNK1/2 short hairpin RNA (shJNK1/2)– expressing, 
PIN1 short hairpin RNA (shPIN1)– expressing cells 
were injected subcutaneously into dorsal regions of 
8- week- old female NOD/SCID (strain 394, Charles 
River) immunodeficient mice. Body weight and tumor 
sizes were recorded over time by a caliper, and tumor 
volumes were calculated using the formula L × W2× 
0.52, where L and W represent the length and width, 
respectively. For ATRA treatment, 2 weeks later 
mice injected with CCLP1 parental cells were ran-
domly selected to receive ATRA or control (placebo) 
treatment using time- release (over 21 days) drug pel-
lets. For implantation, placebo or 10  mg of ATRA- 
releasing pellets (Innovative Research of America, 
Sarasota, FL) were implanted subcutaneously in the 
flank of tumor- bearing NOD/SCID mice. At sacri-
fice, the tumors were recovered, photographed, and the 
wet weight of each tumor was recorded. Each tumor 
was snap- frozen for further analysis. All experiments 
were carried out with approval from the UK Home 
Office Authority (PPL70/8448; PEA0105B1).(31)
StatIStICal aNalySIS
Statistical analyses were performed with Prism 9.0 
(GraphPad Software). For two pairwise comparisons, 
two- tailed Student t tests were performed. One- way 
ANOVA was performed to determine differences 
between each group when more than two conditions 
were present. A two- way ANOVA test was used 
to test the effect of two independent variables on a 
dependent variable. Error bars represent the SEM. A 
value of P < 0.05 was considered significant.
Additional methods are provided as Supporting 
Material.
Results
JNK aCtIVIty CoRRelateS 
WItH pIN1 eXpReSSIoN aND 
RegUlateS ItS pRoteIN leVelS 
IN CHolaNgIoCaRCINoMa
As RAS mutations are a key event in cholangio-
carcinogenesis,(4- 7) and both PIN1 and JNK activa-
tion were previously identified as downstream targets 
of oncogenic RAS,(9- 11,16,20) we investigated a possi-
ble relationship between PIN1 and JNK signaling in 
ICC. First, we analyzed the expression levels of PIN1 
and phospho- JNK (p- JNK; a proxy for active JNK) 
in consecutive sections of ICC TMA by immuno-
histochemistry using antibodies of anti- PIN1(28) or 
anti- p- JNK,(29) which detect phosphorylated JNK1 
and JNK2, two major JNK kinases. We found that, 
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compared with adjacent nontumor biliary cells, an 
increased percentage of ICC epithelial cells expressed 
PIN1 (18.64 vs. 41.25) and p- JNK (6.19 vs. 20.13), 
the levels of which positively correlated each other 
(Fig.  1A,B and Supporting Fig.  S1A). Using west-
ern blot (WB), we then evaluated the expression of 
PIN1 and p- JNK in ICC- derived cell lines (CCLP1, 
HuCCT1, and SG231) and observed higher levels 
of both PIN1 and p- JNK in all three ICC cell lines 
when compared with primary normal intrahepatic 
biliary epithelial cells (Fig.  1C). Moreover, analysis 
of JNK activation by in vitro kinase assays showed 
considerable increase of the kinase activities of JNK1 
and JNK2 in ICC cells compared with nontumoral 
immortalized human H69 cholangiocytes,(32) whereas 
the overall PIN1 protein levels were similar in ICC 
and H69 cells (Fig. 1D), suggesting a potential JNK- 
PIN1 pathway that is specific to ICC.
Next, we knocked down the expression of JNK 
proteins in ICC cells using short hairpin RNA 
(shRNA) lentiviruses targeting both JNK1 and JNK2 
(shJNK1/2), and analyzed PIN1 expression levels. 
As controls, we used lentiviruses expressing shNS.(29) 
Efficient knockdown was verified by WB (Fig.  1E). 
Knockdown of JNK1/2 resulted in a marked reduc-
tion of PIN1 protein levels (Fig.  1E) with no sig-
nificant effect on PIN1 mRNA levels (Fig.  1F), 
suggesting that JNK proteins regulate PIN1 at 
the post- transcriptional level. Similar results were 
obtained in ICC cells depleted of either JNK1 or 
JNK2 (Supporting Fig. S1B,C). Intriguingly, reduced 
PIN1 protein levels were not observed in JNK1/2- 
silenced H69 cells (Fig.  1E). This indicates that 
the effect of JNK on PIN1 expression is specific to 
ICC cells, in which JNK is constitutively active (see 
Fig.  1C,D). Indeed, a decrease in PIN1 protein lev-
els was observed when we treated ICC cells with the 
JNK inhibitor SP600125(33) (Fig.  1G), which spe-
cifically blocked phosphorylation/activity of JNK1/2 
without affecting phosphorylation/activity levels of 
other related MAPK proteins (ERK and p38).(9) 
Remarkably, no significant differences in phosphory-
lation/activity levels of JNK were observed when we 
knocked down PIN1 expression in ICC cells using 
shPIN1 (Supporting Fig.  S1D), which is consis-
tent with the hypothesis that JNK proteins function 
upstream of PIN1. Moreover, WB of lysates from 
CCLP1 cells infected with a lentivirus expressing 
a constitutively active form of JNK1 ( JNK1CA)(30) 
revealed that expression levels of endogenous PIN1 
were increased compared with control cells (Fig. 1H), 
suggesting a role for JNK activity in up- regulating 
PIN1 protein levels.
pIN1 FUNCtIoNally 
MIMICS JNK aCtIVatIoN IN 
CHolaNgIoCaRCINoMa CellS
Because JNK activity positively regulates PIN1 
protein levels (Fig. 1E,G,H and Supporting Fig. S1B) 
and its inhibition impairs ICC cell proliferation,(8) 
we investigated whether this was the case for PIN1. 
Compared with control silencing, knockdown of 
PIN1 significantly attenuated the growth rate and 
reduced the colony- forming ability of ICC cells to 
the same extent as JNK1/2 knockdown (Fig.  2A- 
D and Supporting Fig.  S2A- C). The growth defect 
of PIN1- depleted cells was specific to the lack of 
PIN1, as reconstituted expression of shRNA- resistant 
wild- type (WT) PIN1 (rPIN1 WT) in these cells 
reversed this defect (Supporting Fig.  S2D). The 
effects of knockdown of either PIN1 or JNK1/2 were 
also confirmed by decreased cell mass accumulation 
(Supporting Fig. S2E- G). Notably, depletion of either 
PIN1 or JNK1/2 had no effect on the growth rate or 
cell mass accumulation of H69 cells (Fig.  2A,B and 
Supporting Fig. S2E- G). Furthermore, we observed a 
significant reduction of bromodeoxyuridine incorpo-
ration in PIN1 knockdown cells with a concomitant 
decrease in the levels of various cell- cycle regula-
tors (Supporting Fig.  S2H,I), indicating that PIN1 
depletion attenuates ICC cell proliferation. These 
reductions occurred in the absence of any significant 
induction of apoptosis, as determined by measure-
ment of the percentage of the sub- G1 population and 
caspases cleavage (Supporting Fig.  S2J,K). Similar 
results were observed in JNK1/2 knockdown cells 
(Supporting Fig.  S2L- O). Moreover, when subcuta-
neously injected into NOD/SCID immunodeficient 
mice, CCLP1 cells with PIN1 or JNK1/2 knockdown 
gave rise to smaller tumors compared with those of 
control silencing, as revealed by measuring tumor 
mass and weight (Fig.  2E- H). In contrast to the 
effects induced by PIN1 depletion, ectopic expression 
of PIN1 led to a significant increase in growth rate 
and colony formation of ICC cells (Fig.  2I,J). These 
effects faithfully mimicked those of JNK1CA overex-
pression (Fig.  2K,L). Together, these results indicate 
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that PIN1 promotes ICC cell proliferation both in 
vitro and in vivo to a similar degree as JNK activation 
and suggest that JNK inhibition may impair ICC cell 
proliferation by lowering PIN1 levels.
JNK INHIBItIoN DeCReaSeS 
pIN1 leVelS By pRoMotINg ItS 
MoNoUBIQUItIN- pRoteaSoMe 
DegRaDatIoN
The observation that JNK1/2 knockdown results 
in a decrease in PIN1 protein levels without affecting 
the levels of its mRNA (Fig.  1E,F and Supporting 
Fig. S1B,C) led us to examine whether JNK1/2 reg-
ulated PIN1 protein stability. For this purpose, we 
evaluated the half- life of PIN1 by performing pulse- 
chase assays in the presence of cycloheximide (CHX), 
which blocks protein synthesis. Depletion of JNK1/2 
or chemical inhibition of JNK activity resulted in 
a decrease in the half- life of endogenous PIN1 in 
CCLP1 cells (Fig.  3A,B). Conversely, co- expression 
of JNK1CA but not a catalytically nonactive JNK1 
protein resulted in an increase of the half- life of PIN1 
in HEK293T cells (Supporting Fig.  S3A,B). These 
findings indicate that active JNK1/2 up- regulate 
PIN1 levels by enhancing its protein stability.
As PIN1 has been reported to be degraded 
through the ubiquitin- proteasome system,(34- 36) we 
examined whether JNK proteins elicit their effects on 
PIN1 stability through inactivation of the ubiquitin- 
proteasome system.(37) Treatment of JNK1/2- depleted 
ICC cells with the proteasome inhibitor MG132 was 
sufficient to completely revert the decrease in PIN1 
protein levels in these cells (Fig. 3C), indicating that 
proteasome mediates the effects of JNK1/2 deple-
tion on PIN1 levels. Similar results were obtained 
when we added MG132 to ICC cells pretreated 
with SP600125 to inhibit JNK activity (Fig.  3D). 
We then asked whether JNK could affect PIN1 
ubiquitination, a key post- translational modification 
required for proteasomal degradation. FLAG- tagged 
PIN1 and His- tagged ubiquitin were co- expressed 
in HEK293T cells with or without HA- tagged 
JNK1CA, and the ubiquitination status of PIN1 was 
assessed by combined Ni- NTA pull- down (PD) and 
WB analyses. Expression of JNK1CA prevented the 
appearance of a single band corresponding in molec-
ular weight to the mono- ubiquitinated form of PIN1 
(Supporting Fig. S3C). Such an effect was also con-
firmed by co- immunoprecipitation (IP) analyses 
(Supporting Fig. S3D). Similar results were obtained 
when a mutant form of ubiquitin (UbK0), which 
allows only mono- ubiquitination due to the lack of 
lysine residues,(38) was used instead of WT ubiquitin 
(Supporting Fig.  S3E). This confirms that PIN1 is 
subject to mono- ubiquitination, which is inhibited by 
FIg. 1. Active JNK positively correlates and regulates PIN1 levels in human ICC. (A) Immunohistochemistry on serial sections of 42 
paired nontumor adjacent (left panels) and ICC tissue (right panels) stained for p- JNK and PIN1. Dot plots graphs indicate the percentage 
of biliary cells positively stained for p- JNK and PIN1 in nontumor and ICC tissue (n = 42 per group). Data shown in the ICC group are the 
average results of duplicate samples. Data are presented as mean ± SEM; circles represent individual data points. P value was determined 
by Wilcoxon matched- pairs signed- rank test. Photomicrographs: scale bars = 300 μm (top) and 100 μm (bottom); magnification = ×10 
(top) and ×40 (bottom). (B) Scatterplots showing the positive correlation between p- JNK and PIN1 protein expression in nontumor 
adjacent and ICC tissue. Pearson’s coefficient tests were performed to assess statistical significance. (C) WB analyses detecting p- JNK 
and PIN1 in lysates of normal HIBEpiC and ICC- derived cell lines (CCLP1, HuCCT1, and SG231). Actin and total JNK were used 
as loading control. Arrows denote the expression levels of spliced variants p46 and p54 of JNK1 and JNK2. (D) WB and kinase assay 
analyses detecting PIN1 expression and JNK1 and JNK2 kinase activities in indicated ICC cell lines and nontumoral human immortalized 
cholangiocytes (H69).(32) Actin and total JNK1 and JNK2 protein levels were used as loading control. (E) WBs showing a reduction of 
PIN1 levels in indicated ICC cell lines but not in H69 cells infected with lentiviruses expressing shJNK1/2 compared with control shNS. 
WBs (bottom panels) showing the JNK1/2 knockdown efficiency. The bar graphs represent the quantification of the relative PIN1 levels 
normalized to actin. (F) Bottom: Gel of PIN1 mRNA levels, as detected by real- time PCR, in CCLP1- expressing shJNK1/2 and control 
shNS. Top: Graph showing quantification of the data presented as mean ± SEM; circles represent individual data points. GAPDH, 
control. P value was determined by the Student t test. (G) WB analyses showing a reduction of PIN1 levels in indicated ICC cell lines 
treated with 10 µM JNK inhibitor SP600125 compared with vehicle (DMSO)– treated control. Detection of p- JNK, p- c- Jun, p- p38, 
and p- ERK is shown to demonstrate effective inhibition of specific JNK kinase activity. Tubulin, control. The bar graphs represent the 
quantification of the relative PIN1 levels normalized to tubulin. (H) WB analyses showing increased expression of PIN1 in CCLP1 cells 
infected with lentiviruses expressing FLAG- tagged constitutive active JNK1 (FLAG- JNK1CA) compared with EV. Actin, control. The bar 
graphs represent the quantification of the relative PIN1 levels normalized to actin. Results are representative of at least three independent 
experiments. Abbreviations: GAPDH, glyceraldehyde 3- phosphate dehydrogenase; HIBEpiC, human primary cholangiocytes; K.A., 
kinase assay; p- ERK, phosphorylated extracellular signal- regulated kinase.
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JNK1CA expression. Such inhibition was not observed 
when we co- expressed the catalytically nonactive 
JNK1 protein (Supporting Fig. S3F), suggesting that 
JNK kinase activity is required for preventing PIN1 
mono- ubiquitination. Importantly, the inhibitory 
effect of JNK on PIN1 mono- ubiquitination was con-
firmed in ICC cells, as accumulation of endogenous 
mono- ubiquitinated PIN1 was observed in JNK1/2- 
depleted CCLP1 cells (Fig.  3E). Thus, the constitu-
tive activation of JNK in ICC cells leads to high levels 
of PIN1 by preventing its mono- ubiquitination and 
degradation.
aCtIVe JNK pRoteINS INteRaCt 
WItH aND pHoSpHoRylate pIN1 
at Ser115
To gain insight into the mechanism by which 
JNK proteins stabilize PIN1, we co- expressed HA- 
tagged PIN1 in HEK293T cells with FLAG- tagged 
JNK1CA, FLAG- tagged JNK2CA or empty vector, 
and investigated protein associations by combined IP 
and WB analyses. Both FLAG- tagged JNK1CA and 
FLAG- tagged JNK2CA specifically bound to HA- 
PIN1 (Supporting Fig.  S4A). Furthermore, in vitro 
kinase assays revealed that both active JNK1 and 
JNK2 efficiently phosphorylated recombinant glu-
tathione S- transferase (GST)– fused PIN1, but not 
GST alone (Fig.  4A). As JNK1 and JNK2 shared 
common function with respect to their interaction 
with PIN1 and its phosphorylation, we focused our 
attention on JNK1 in further analyses. First, the inter-
action between PIN1 and active JNK1 was confirmed 
at the endogenous levels. Anti- active JNK1 antibod-
ies(29,30) co- immunoprecipitated PIN1 from paren-
tal cells, but not from ICC cells depleted of PIN1 
(WB:PIN1; Fig. 4B). JNK1 was immunoprecipitated 
at comparable levels in both parental cells and PIN1- 
depleted cells and was not co- precipitated by isotype- 
matched control antibodies (WB:JNK1; Fig. 4B). We 
then verified that PIN1 was phosphorylated by JNK1 
in in vivo cells. PIN1 co- expressed with JNK1CA, but 
not with the catalytically nonactive JNK1 protein, was 
highly phosphorylated in HEK293T cells, as shown 
by a marked band shift of PIN1 on Phos- tag poly-
acrylamide gel electrophoresis.(39) This shifted band 
disappeared when cell lysates were treated with the 
calf intestinal alkaline phosphatase (CIP) (Supporting 
Fig. S4B), confirming that the shifted band of PIN1 
was a consequence of phosphorylation by active JNK1. 
Importantly, phosphorylation of endogenous PIN1 by 
JNK was confirmed in ICC cells, as the PIN1- shifted 
band disappeared in JNK1/2- depleted or SP600125- 
treated CCLP1 cells on Phos- tag immunoblots 
(Fig. 4C), indicating that PIN1 is indeed phosphory-
lated by JNK proteins in ICC cells.
To test whether JNK could directly phosphorylate 
PIN1, we performed in vitro kinase assays and found 
that recombinant active JNK1 efficiently phosphor-
ylated purified His- PIN1 (Fig.  4D). Accordingly, in 
vitro pull- down analyses revealed direct interaction 
between active JNK1 and PIN1 (Fig. 4E). Altogether, 
these data indicate that PIN1 is a direct substrate 
of JNK1 kinase. In support of this notion, a single 
phosphorylation site (Ser115) was detected in PIN1 
by mass spectrometry (Supporting Fig.  S4C- F). 
FIg. 2. JNK activity and PIN1 expression are similarly required for ICC cell growth both in vitro and in vivo. (A,B) Growth curves of 
CCLP1 (n = 6), HuCCT1 (n = 6), SG231 (n = 3), and nontumoral H69 cholangiocytes (n = 3) stably expressing PIN1, JNK1/2, or shNS. 
Data are shown as mean ± SEM and are representative of three independent cultures. (C,D) Anchorage- independent colony formation of 
CCLP1 and SG231 cells stably expressing shPIN1, shJNK1/2, or shNS. Representative images show overall view of colony growth after 
3 weeks. Data shown are mean ± SEM of three independent cultures, and circles represent individual data points. P values were calculated 
by Student t test. (E) WBs showing PIN1 and JNK1/2 protein levels in lysates from CCLP1 cells stable- expressing shNS, shJNK1/2, or 
shPIN1 used in xenograft experiments (injected cells). Tubulin and total JNK levels were analyzed with appropriate antibodies as controls. 
The bar graphs represent the quantification of the relative PIN1 levels normalized to tubulin. (F) Curves of tumor volume plotted over 
time following inoculation of CCLP1 cells described in (E). P values were calculated using the two- way ANOVA test. (G) Shown are 
sizes of tumors developed in mice 24 days following inoculation with CCLP1 cells as described in (E). (H) Tumor weight of explanted 
tumors at day 24 following post- inoculation. P values were calculated from one- way ordinary ANOVA test adjusted with Tukey’s multiple 
comparison tests. (I,K) Growth curves and anchorage- independent colony formation of CCLP1 ectopically expressing either FLAG- 
PIN1 (n = 3) (I) or FLAG- JNK1CA (n = 3) (K) compared with EV (n = 3). Shown are representative light microscopy images of cultured 
cells (days 7 or 8 after complementary DNA expression) and overall view of colony growth after 3 weeks. Data shown are mean ± SEM 
of three independent cultures; circles represent individual data points. P values were calculated by Student t test. ( J,L) WBs showing the 
ectopic or endogenous (endog.) levels of PIN1 and p- JNK in CCLP1 stably expressing FLAG- PIN1 ( J) or FLAG- JNK1CA (L).
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Sequence alignment analysis of PIN1 revealed that 
Ser115 is conserved among different species and 
located within the consensus phosphorylation motif 
for JNKs (115SA116)(40) (Supporting Fig.  S4G). To 
confirm Ser115 as the specific JNK1 phosphoryla-
tion site on PIN1, a non- phosphorylatable alanine 
PIN1 mutant (S115A) was generated and used as a 
substrate for JNK1 in kinase assays. As controls, we 
individually mutated Ser114, a nearby JNK consen-
sus phosphorylation site (114SS115), and Ser138, a res-
idue known to be phosphorylated by the JNK- related 
kinase mixed- lineage kinase 3,(41) into alanines 
(S114A and S138A). PIN1- S115A mutant, but not 
WT PIN1, PIN1- S114A or PIN1- S138A mutant, 
was resistant to phosphorylation by JNK1 in vitro 
(Fig.  4F). This result was confirmed in ICC cells 
expressing endogenous active JNK and in HEK293T 
cells expressing exogenous constitutively active JNK1 
by Phos- tag immunoblots (Fig.  4G and Supporting 
Fig. S4H). Taken together, these results indicate that 
JNK1 directly phosphorylates PIN1 at Ser115 both in 
vitro and in in vivo cells.
FIg. 3. Constitutive activation of JNK stabilizes PIN1 protein by preventing its mono- ubiquitination and degradation. Results shown are 
representative of at least three independent experiments. (A) Analysis of PIN1 protein stability by pulse- chase experiments in JNK1/2- 
depleted CCLP1 cells. WB analyses of PIN1 levels in shJNK1/2- expressing and shNS- expressing CCLP1 cells treated with CHX for the 
indicated times. Quantification of PIN1 levels relative to tubulin is shown on the right panel. (B) WB analyses of PIN1 levels in CCLP1 
cells pretreated with SP600125 (10 µM) for 24 hours, followed by CHX treatment for the indicated times. Quantification of PIN1 levels 
relative to tubulin is shown on the right panel. (C) WBs showing PIN1 abundance in JNK1/2- depleted CCLP1 cells treated with either 
10 µM MG132 or DMSO (control) for 24 hours. The bar graphs represent the quantification of the relative PIN1 levels normalized to 
actin. shNS- expressing CCLP1 cells are used as control. (D) WBs showing PIN1 abundance in CCLP1 treated with SP600125 (10 µM) 
for 24 hours followed by co- treatment of SP600125 with either 10 µM MG132 or DMSO (control) for an additional 24 hours. The bar 
graphs represent the quantification of the relative PIN1 levels normalized to actin. Parental CCLP1 cells treated with DMSO alone are 
used as control. (E) In vivo ubiquitination assays showing accumulation of endogenous mono- ubiquitinated PIN1 in JNK1/2- depleted 
CCLP1 cells overexpressing His- HA- tagged ubiquitin, in the presence of MG132. Ubiquitinated proteins were pulled down with Ni- 
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pHoSpHoRylatIoN oF 
pIN1 at Ser115 pReVeNtS ItS 
MoNo- UBIQUItINatIoN aND 
DegRaDatIoN
To directly test the role of Ser115 phosphory-
lation in the control of PIN1 protein stability, we 
generated CCLP1 cells stably expressing FLAG- 
PIN1- WT, FLAG- PIN1- S114A, FLAG- PIN1- 
S115A, or FLAG- PIN1- S138A mutant and assessed 
the half- life of PIN1 mutant proteins in these cells, 
which have endogenous active JNK (Fig.  1C,D). 
Endogenous active JNK failed to prolong the half- life 
of the PIN1- S115A mutant, but not of PIN1- WT, 
PIN1- S114A, or PIN1- S138A mutant (Fig.  5A), 
implying that phosphorylation of PIN1 at Ser115 
is required for PIN1 protein stability. Accordingly, 
PIN1- S115A mutant was heavily mono- ubiquitinated 
in CCLP1 cells, whereas WT PIN1 was resis-
tant to mono- ubiquitination (Fig.  5B), indicating 
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that PIN1- S115A mutant is targeted for degrada-
tion. Similar results were observed in HEK293T 
cells ectopically expressing JNK1CA (Supporting 
Figs. S5A,B and S3C). Collectively, these data indi-
cate that JNK- mediated PIN1 phosphorylation at 
Ser115 is essential for PIN1 protein stability. We 
next sought to identify the lysine residue on PIN1, 
which is targeted for mono- ubiquitination. As most 
protein ubiquitination sites tend to be exposed to the 
solvent,(42,43) we calculated the solvent- accessible sur-
face area (SASA) of the 10 lysine residues (K6, K13, 
K46, K63, K77, K82, K95, K97, K117, and K132) in 
the high- resolution X- ray crystal structure of PIN1 
(PDB ID:1PIN).(44) Lys117 emerged as the lysine 
residue with the highest solvent accessibility (Fig. 5C 
and Supporting Table S1), suggesting that K117 is a 
highly exposed residue and may therefore serve as the 
PIN1 ubiquitination site. Indeed, mutation of Lys117 
to arginine (K117R) abolished mono- ubiquitination 
of PIN1 (Fig.  5D and Supporting Fig.  S5C), and 
subsequently resulted in an increase of PIN1 half- life 
in in vivo cells (Fig.  5E and Supporting Fig. S5D). 
Although we cannot completely rule out by site- 
directed mutagenesis that other lysine residues within 
PIN1 could be targets for mono- ubiquitination, 
mutating Lys46, which has the second highest sol-
vent accessibility, did not abrogate the ubiquitination 
of PIN1 (Supporting Fig.  S5C). These results indi-
cate that, most likely, Lys117 residue on PIN1 is the 
major site subjected to mono- ubiquitination needed 
for its degradation.
To gain insights into the structural basis of Ser115 
phosphorylation- mediated inhibition of PIN1 mono- 
ubiquitination, we performed atomistic molecular 
dynamics (MD) simulations in explicit solvent of 
unphosphorylated Ser115 (S115) and phosphorylated 
Ser115 (p- S115) PIN1 (Supporting Fig. S5E; see also 
Supporting Methods). Five independent MD simula-
tions of 100 ns were carried out for each Ser115 state, 
starting from the crystallographic coordinates of PIN1 
resolved at 1.35  Å.(44) Comparison of the atomic 
RMS deviations (RMSDs) from the starting structure 
revealed that, although both unphosphorylated and 
phosphorylated PIN1 displayed low deviations with 
respect to the X- ray structure, phosphorylated PIN1 
showed higher deviations compared with the unphos-
phorylated PIN1 (Supporting Fig. S5F,G). Consistent 
with the RMSD results, analyses of the atomic RMS 
fluctuations revealed a significant increase in the flex-
ibility of residues 115- 117 upon phosphorylation of 
Ser115 (Supporting Fig.  S5H). Taken together, our 
simulations suggest that phosphorylation at Ser115 
induces significant local changes in the dynamics 
of PIN1. Interestingly, analyses of the SASA value 
for the 10 lysine residues of PIN1 throughout the 
MD simulations revealed a significant decrease in 
the solvent accessibility of Lys117 upon phosphor-
ylation of Ser115 (Supporting Fig.  S5I). All other 
lysine residues displayed no significant differences 
in the average SASA values between the unphos-
phorylated and phosphorylated PIN1 systems 
(Fig.  5F). Representative snapshots from one of the 
FIg. 4. JNK directly binds to and phosphorylates PIN1 at Ser115. Results shown are representative of at least three independent 
experiments. (A) Constitutive active JNK1 or JNK2 were immunoprecipitated from lysates of HEK293T cells expressing FLAG- tagged 
JNK1CA or FLAG- JNK2CA, respectively, and assayed for kinase activity using recombinant GST- PIN1 or control GST proteins as 
substrates in the presence of (32P)- γ- ATP. WB and Coomassie blue staining indicate loading controls in the bottom panels. (B) IP 
followed by WBs showing endogenous association of active JNK1 with PIN1 in parental CCLP1 cells. IP against IgG and lysates of 
PIN1- depleted (shPIN1) CCLP1 cells were used as control. The purple- colored asterisks indicate PIN1 band present in the anti- PIN1 
blot. (C) Phos- tag analysis in JNK1/2- depleted or SP600125- treated CCLP1 ICC cells showing reduction of endogenous phospho(p)- 
PIN1 levels compared with control cells (shNS; DMSO). Tubulin, loading control. (D) In vitro JNK kinase assay was performed by 
incubating recombinant activated JNK1 with His- PIN1 as substrate. [32P]- Rec. active- JNK1 denotes autophosphorylation. Coomassie 
staining shows the purity and size of the recombinant proteins. (E) In vitro PD assay showing a direct binding between purified active JNK1 
and PIN1. The assay was performed by IP and WB after incubating purified recombinant activated JNK1 and His- PIN1 (IP:JNK1 and 
WB:PIN1). (F) Activated JNK was immunoprecipitated from lysates of HEK293T cells expressing FLAG- tagged JNK1CA and assayed 
for kinase activity using purified His- tagged PIN1- WT, PIN1- S114A, PIN1- S115A, or PIN1- S138A as substrate in the presence of 
(32P)- γ- ATP. WB against p- JNK and Coomassie staining indicate loading controls. (G) Phos- tag analysis of PIN1 S115 phosphorylation 
by endogenous JNK in CCLP1 cells stably expressing PIN1- WT or the indicated PIN1 mutants. Phosphorylated PIN1 band is absent in 
CCLP1 cells expressing FLAG- PIN1(S115A) mutant. An aliquot of lysates from CCLP1 cells expressing FLAG- PIN1- WT was treated 
with CIP before electrophoresis and loaded onto the same gel on a distant lane. All of the other samples were incubated at 37°C in the 
presence of CIP buffer only. Bottom: Standard WBs were carried on whole- cell lysates using anti- FLAG antibody. Abbreviations: K.A., 
kinase assay; Rec. active- JNK1, recombinant activated JNK1.
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five simulations of phosphorylated PIN1 are shown 
in Supporting Fig.  S5J, to illustrate the decrease in 
the SASA of K117 (from 165 Å to 68 Å) during the 
course of the simulation time. These observations sug-
gest that PIN1 phosphorylation at Ser115 may inhibit 
its mono- ubiquitination by decreasing surface expo-
sure of the Lys117 residue, and thus its accessibility, 
for ubiquitination.




We then examined the biological significance of 
JNK- mediated PIN1 Ser115 phosphorylation on 
PIN1 function in ICC cells. ICC cells depleted of 
endogenous PIN1 were reconstituted with rPIN1 
WT, shRNA- resistant PIN1 S115A (rPIN1 S115A) 
or empty vector (EV), and growth rate and colony- 
forming capacity of ICC cells were evaluated. Ectopic 
expression of rPIN1 WT and rPIN1 S115A was 
verified by WB (Fig.  6A). Of note, rPIN1 WT and 
rPIN1 S115A had comparable cellular levels that 
were similar to those of endogenous PIN1 in paren-
tal cells (Fig.  6A; top panel). In parallel, Phos- tag 
WB analyses further confirmed that S115A mutation 
abolishes JNK- mediated phosphorylation signal in 
ICC cells (Fig. 6A; see also Fig. 4C). Reconstitution 
with rPIN1 S115A, but not rPIN1 WT, failed to res-
cue the impaired growth rate and ability to grow col-
onies of PIN1- depleted cells (Fig.  6B,C). Moreover, 
expression of key positive cell- cycle regulators and 
transcriptional activity of NF- κB (a well- established 
PIN1 target and ICC cell growth marker)(20,45) were 
restored by reconstituted expression of rPIN1 WT, 
but not by that of rPIN1 S115A mutant (Fig. 6A,D). 
Thus, phosphorylation of PIN1 at Ser115 by active 
JNK is critical for promoting ICC cell proliferation.
pHaRMaCologICal 
INHIBItIoN oF pIN1 IMpaIRS 
CHolaNgIoCaRCINoMa 
gRoWtH
The prolific role of PIN1 in cancer has triggered 
extensive efforts to design small molecule inhibitors 
targeting PIN1 function.(19- 24,36) One such potent 
inhibitor of PIN1 is ATRA, which binds to PIN1 
and induces its degradation.(27,36) As the JNK- PIN1 
regulatory axis sustains ICC cell proliferation, we 
explored whether ATRA- induced PIN1 degradation 
could be used as a therapeutic strategy in cholangio-
carcinoma. First, we treated ICC cells with increasing 
concentrations of ATRA and observed that ATRA 
treatment resulted in a dose- dependent decrease in 
the growth rate of ICC cells; however, ATRA had no 
effect on nontumoral H69 cholangiocytes (Fig.  7A). 
FIg. 5. JNK- mediated PIN1 Ser115 phosphorylation prevents its mono- ubiquitination at Lys117. Results shown are representative of at 
least three independent experiments. (A) Analysis of PIN1 WT and PIN1 mutant proteins stability by pulse- chase experiments. CCLP1 
cells overexpressing FLAG- tagged PIN1- WT or PIN1 mutants (S114A, S115A, and S138A) were treated with CHX for the indicated 
times, harvested, and analyzed by WBs as indicated. Quantification of FLAG- PIN1 levels relative to tubulin is shown on the right panel. 
(B) In vivo ubiquitination assays showing the level of mono- ubiquitination of PIN1- WT and PIN1- S115A mutant proteins in CCLP1 
cells stably co- expressing His- HA- ubiquitin with FLAG- PIN1- WT or FLAG- PIN1- S115A, in the presence of MG132. Ubiquitinated 
proteins were pulled down with Ni- NTA beads and analyzed by WB using anti- FLAG antibody. (C) Ribbon representation of PIN1 
color- coded by domain (gray, WW domain; blue, PPIase domain). The 10 lysine residues of the enzyme are shown with ball- and- sticks 
(green C, blue N, and white H atoms), and values in parentheses indicate the relative solvent accessibility of their side- chain atoms 
(RSA, %), as calculated from a high- resolution crystal structure of PIN1 (PDB ID: 1PIN) using NACCESS. Also shown with orange C 
atoms are S115, C113, and the catalytic site histidine residues H59 and H157 (O atoms are shown in red and S in yellow). (D) In vivo 
ubiquitination assay in SP600125- treated CCLP1 cells stably co- expressing His- HA- ubiquitin with FLAG- PIN1- WT or FLAG- PIN1- 
K117R. Left: Ubiquitinated proteins were pulled down with Ni- NTA beads and analyzed by WBs using anti- FLAG antibody. Right: 
IP with anti- FLAG antibody followed by WBs with anti- ubiquitin antibody. (E) Analysis of PIN1- WT and PIN1- K117R proteins 
stability by pulse- chase experiments. Following treatment with SP600125, CCLP1 cells overexpressing FLAG- PIN1- WT or FLAG- 
PIN1- K117R mutant were treated with CHX for the indicated times, harvested, and analyzed by WB as indicated. Quantification of 
FLAG- PIN1 levels relative to tubulin is shown on the right panel. (F) Left: Plot of the mean SASA for each lysine residue of PIN1 
(side- chain atoms only), calculated from (n = 5) independent 100- ns MD simulations of the enzyme in the unphosphorylated (S115) or 
phosphorylated (p- S115) state of Ser115. Data in bar graph are presented as mean ± SEM; circles represent individual data points. P values 
were calculated using the multiple t- test. Right: Volcano plot showing the estimated SASA fold changes between S115 and p- S115 (x- 
axis) versus the −log10 P values (y- axis) for each lysine of PIN1. Dotted grid lines are shown at x = 0 (no difference) and y = −log10(0.05). 
K117 is the only lysine showing a significant difference. Abbreviation: Ub, ubiquitin.
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As expected, the decrease in the cell growth rate was 
associated with a dose- dependent decrease in PIN1 
protein levels (Fig.  7B), confirming that ATRA 
 prevents PIN1 accumulation in ICC cells. Notably, 
ATRA treatment did not affect the phosphorylation/
activity levels of JNK (Fig.  7B). A dose- dependent 
growth inhibitory effect of ATRA was also observed 
in ICC cells ectopically expressing PIN1 (Fig.  7C). 
Next, we subcutaneously injected CCLP1 cells into 
NOD/SCID immunodeficient mice, and 2 weeks 
later we implanted either ATRA- releasing pellets 
or placebo pellets into the flanks of mice to assess 
the effects of ATRA on the ability of ICC cells to 
form tumors in vivo (Supporting Fig.  S6A). After 
a median tumor growth period of 26  days, smaller 
tumors developed in ATRA- treated group compared 
with those in placebo- treated mice, as revealed by 
measuring tumor mass and tumor weight (Fig. 7D- F 
and Supporting Fig. S6B). WB analyses showed that 
PIN1 levels markedly decreased in the ATRA- treated 
tumors compared with those in placebo- treated 
tumors (Supporting Fig.  S6C). Notably, expression 
levels of PIN1 did not correlate with those of p- JNK 
in tumors from ATRA- treated mice (Supporting 
Fig.  S6C; see also Fig.  7B), suggesting a potential 
disruption of JNK- PIN1 regulatory axis by ATRA. 
These results suggest that ATRA- induced PIN1 
degradation may have therapeutic potential against 
FIg. 6. PIN1 Ser115 phosphorylation promotes ICC cell growth. (A) Representative of three independent WBs showing the effect 
of PIN1 reconstitution in CCLP1 cells depleted of endogenous PIN1. Cells were reconstituted with complementary DNA expressing 
shRNA- resistant FLAG- PIN1 WT (rPIN1 WT), FLAG- PIN1 S115A (rPIN1 S115A), or EV (- ). Lysates of CCLP1 parental cells (first 
lane) were used as control for endogenous PIN1 expression levels. Shown are Phos- tag and classic WB analyses displaying a correlation 
of expression between phospho(p)- PIN1 levels and cyclin D1, E, and A. Tubulin was used as loading control. (B) shPIN1- expressing 
CCLP1 and SG231 ICC cells were reconstituted with rPIN1 WT, rPIN1 S115A or EV, and cell growth was quantified at the indicated 
times. Data are presented as mean ± SEM. (C) Colony- formation assay was performed in shPIN1- expressing CCLP1 and SG231 cells 
reconstituted with rPIN1 WT, rPIN1 S115A, or EV. Data are presented as mean ± SEM, and circles represent individual data points. P 
values were calculated using the one- way ordinary ANOVA test adjusted with Dunnett’s multiple comparison tests. (D) Transcriptional 
activity of NF- κB (left) and signal transducer and activator of transcription 3 (right) in shPIN1- expressing CCLP1 cells reconstituted 
with rPIN1 WT, rPIN1 S115A, or EV. Data are presented as mean ± SEM; circles represent individual data points. P values were 
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cholangiocarcinoma growth. Finally, we examined 
the biological importance of JNK- mediated PIN1 
Ser115 phosphorylation in the response of ICC cells 
to ATRA. Compared with PIN1- depleted ICC cells 
reconstituted with rPIN1 WT, PIN1- depleted ICC 
cells reconstituted with rPIN1 S115A mutant were 
much less sensitive to ATRA- induced growth inhi-
bition (Fig.  7G), implying that PIN1 Ser115 phos-
phorylation is crucial for the susceptibility of ICC 
cells toward ATRA.
Discussion
Activation of the JNK signaling pathway in cholan-
giocytes is a key event in cholangiocarcinogenesis and 
a promising target in ICC therapy.(8) However, due 
to its multifunctional role in liver homeostasis,(12- 15) 
the development of selective therapies that target JNK 
directly are unlikely to result in clinically translatable 
options.(9,40,46) Therefore, understanding the mecha-
nism through which JNK activation promotes ICC 
growth and the identification of downstream effectors 
as druggable targets are critical steps for expanding the 
therapeutic management of ICC. Here we uncover a 
mechanistic link between JNK activity and ICC cell 
proliferation through PIN1 protein stabilization and 
demonstrate the potential application of the PIN1 
inhibitor ATRA for ICC therapy.
Elevated levels of PIN1 were found in ICC cell 
lines as well as ICC tissues, and positively correlated 
with the phosphorylation/activity levels of JNK pro-
teins. Intriguingly, the positive association between 
JNK activity and PIN1 levels appears to be specific 
to ICC cells, as it was not observed in nontumoral 
human biliary epithelial cells, in which JNK kinase 
activities are not constitutively up- regulated. While 
blocking JNK activity led to a significant decrease 
in PIN1 protein levels, ectopic expression of a con-
stitutively active form of JNK1 ( JNK1CA) led to an 
increase in endogenous PIN1 protein levels. Thus, 
PIN1 functions downstream of the JNK pathway, 
consistent with the established role of PIN1 in RAS 
signaling.(16,17,20)
PIN1 was first identified as a key regulator of cell 
division and later shown to promote tumorigenesis 
and tumor progression by inactivating proliferation- 
restraining factors or activating proliferation- 
promoting factors.(20- 24) Consistent with the latter, we 
found that PIN1 is essential for proliferation of both 
cultured and xenografted ICC cells and functionally 
mimics JNK activation, thus reflecting the regulatory 
role of JNK activation on PIN1.
What then is the mechanism by which JNK activ-
ity regulates PIN1 expression? Activated JNK pro-
teins regulate a variety of cellular processes, including 
proliferation, by acting on a number of nuclear and 
nonnuclear proteins at either transcriptional or post-
translational levels.(9,40) We found that JNK activity 
regulates the intracellular PIN1 levels by stabilizing 
PIN1 through its phosphorylation, thus prevent-
ing PIN1 mono- ubiquitination and proteasomal 
FIg. 7. PIN1 inhibition by ATRA impairs cholangiocarcinoma growth in vivo. (A) Cell viability assay of CCLP1, HuCCT1, SG231 ICC 
cells, and nontumoral H69 cholangiocytes treated with ATRA for 72 hours and assayed with colorimetric MTT assay. Data are shown as 
mean ± SEM and are the combination of (n = 4) independent cultures. P values were calculated using the two- way ANOVA test. (B) WB 
and quantification analyses showing reduction of PIN1 levels, but not of p- JNK, in CCLP1 and SG231 ICC cell lines following 48 hours 
treatment with the indicated concentrations of ATRA. Tubulin and total- JNK were used as loading controls. (C) Anchorage- independent 
colony formation of CCLP1 expressing FLAG- PIN1 and treated with the indicated concentrations of ATRA. Representative images show 
overall view of colony growth after 3 weeks. Data are shown as mean ± SEM of four independent cultures; circles represent individual data 
points. P values were calculated using the one- way ordinary ANOVA test adjusted with Dunnett’s multiple comparison tests. (D) Shown 
are sizes of tumors developed in nude mice inoculated with CCLP1 cells, and 13 days later implanted with ATRA- releasing (10 mg over 
21 days) or placebo (control) pellets. (E) Tumor weight of explanted tumors at day 26 following ATRA or placebo treatment. P value was 
calculated using the Student t test. (F) Curves of tumor volume plotted over time following ATRA or placebo treatment. P values were 
calculated using the two- way ANOVA test. (G) Cell viability assay of shPIN1- expressing CCLP1 cells reconstituted with rPIN1 WT, 
rPIN1 S115A, or EV and treated with the indicated concentrations of ATRA for 72 hours. Data are shown as mean ± SEM and are the 
combination of three independent cultures. P values were calculated using the two- way ANOVA test. (H) Schematic illustration depicting 
the mechanism of action of JNK- mediated cholangiocarcinogenesis. In response to growth factors, inflammatory cytokines and oncogenic 
signals, cancer cells activate the JNK signaling pathway through a phosphorylation cascade that involves oncogenic RAS, MAP3K, and 
MAP2K. Active JNK directly binds and phosphorylates PIN1 at S115. This phosphorylation prevents PIN1 mono- ubiquitination at 
Lys117 (K117) and subsequent proteasomal degradation, contributing to the intracellular accumulation of PIN1 in cancer cells. The 
targeting of PIN1 with ATRA uncouples the JNK- PIN1 axis and impairs the JNK- mediated cholangiocarcinogenesis. Abbreviations: 
MTT, 3- (4,5- dimethylthiazol- 2- yl)- 2,5- diphenyltetrazolium bromide; P, phosphorylation; Ub, ubiquitin.
Hepatology, Vol. 74, No. 5, 2021 LEPORE, CHOY, ET AL.
2577
degradation. This is demonstrated by showing that 
the newly synthesized endogenous PIN1 displayed 
a shortened half- life in JNK- depleted or SP600125- 
treated ICC cells, and the decreased intracellular pro-
tein levels of PIN1 were reversed by the addition of 
the proteasome inhibitor MG132. In JNK- depleted 
ICC cells, the decrease in PIN1 levels was associated 
with the appearance of a mono- ubiquitinated form of 
PIN1, implying that JNK proteins inhibit the mono- 
ubiquitination of endogenous PIN1. Furthermore, 
JNK kinase activity is strictly required for such inhi-
bition as overexpression of the constitutively active 
form of JNK1, but not its nonactive form, inhibited 
PIN1 mono- ubiquitination. Thus, in accordance with 
previous works showing that protein stability of PIN1 
is regulated through the ubiquitin- proteasome sys-
tem(34- 36) and that small proteins are more likely to be 
mono- ubiquitinated rather than polyubiquitinated for 
degradation,(37,47) constitutive JNK activation prevents 
PIN1 mono- ubiquitination- induced proteasomal deg-
radation, resulting in the stabilization and elevated lev-
els of PIN1. In line with our finding that JNK activity 
is required for preventing PIN1 mono- ubiquitination, 
we show that JNK proteins directly interact with 
and phosphorylate PIN1 at Ser115, thus pinpointing 
PIN1 as a direct downstream target of JNK signaling. 
Moreover, we show that the reconstituted expression 
of non- phosphorylatable PIN1 S115A mutant, which 
was resistant to JNK- mediated suppression of PIN1 
mono- ubiquitination, failed to revert impaired ICC 
cell growth. Therefore, the stabilization of PIN1 upon 
phosphorylation at Ser115 by active JNK represents 
a causal link between JNK activation and high PIN1 
levels, and defines the JNK- PIN1 axis as essential for 
cholangiocarcinoma proliferation.
Given that PIN1 is aberrantly expressed at high lev-
els in various types of tumor, including HCC, B- cell 
lymphoma, brain and lung cancer, in which consti-
tutive JNK activation is commonly observed,(9,20,36) 
we speculate that the JNK- mediated stabilization of 
PIN1 may similarly contribute to the high expression 
of PIN1 in tumors of diverse tissue origin. Notably, 
many downstream effectors of the JNK pathway, 
such as c- Jun and cyclin D1, which promote cancer 
cell proliferation, are reported to be also regulated by 
PIN1.(9,17,20) Interestingly, we found that the reconsti-
tuted expression of PIN1(S115A) mutant but not that 
of rPIN1 WT failed to revert the levels/activities of 
key cell proliferation regulators in ICC cells. Thus, it 
is reasonable to hypothesize that JNK- mediated PIN1 
Ser115 phosphorylation may significantly contribute 
to the pro- proliferative function of activated JNK in 
many human cancers.
Targeting downstream effectors in JNK signal-
ing is a promising approach for inhibition of tumor 
proliferation in JNK- dependent tumors.(9,40,46) Our 
results point to PIN1 as a key downstream effector of 
the JNK pathway and show that the PIN1 inhibitor 
ATRA(36) effectively impaired ICC cell growth both 
in in vitro and xenograft experiments, with a cor-
responding decrease in PIN1 levels but not in JNK 
phosphorylation/activity. Although we cannot rule 
out that other mechanisms of action of ATRA(21,27) 
could also be responsible for its growth inhibitory 
effect in ICC cells, ATRA treatment in ICC cells 
phenocopies the effects of PIN1 knockdown. Thus, 
one would expect that ATRA may interfere with 
the JNK- PIN1 regulatory axis and block its onco-
genic function in ICC, while leaving JNK activation 
unaffected.
The obvious question that remains to be addressed 
is how JNK- mediated Ser115 phosphorylation inhib-
its PIN1mono- ubiquitination. In agreement with the 
notion that protein ubiquitination occurs primarily on 
highly solvent- exposed lysine residues,(42,43) we show 
that the Lys117 of PIN1 is the mono- ubiquitination 
site targeted for proteasomal degradation. Molecular 
dynamics simulations suggest that Lys117 displays a 
decreased solvent accessibility following phosphor-
ylation at Ser115. Therefore, it is likely that JNK- 
mediated Ser115 phosphorylation may shield Lys117 
from intermolecular interactions with components of 
the ubiquitination machinery by decreasing its sur-
face exposure. Future investigations are warranted to 
address this question.
Our findings provide insights into the mechanisms 
by which constitutive JNK activation promotes chol-
angiocarcinoma growth and identify PIN1 as a direct 
downstream target of JNK, revealing an unexpected 
regulatory axis that sustains elevated PIN1 intracellu-
lar levels required for cell proliferation (Fig. 7H). We 
propose that targeting PIN1 using ATRA could be a 
potential therapeutic strategy for ICC. Rapid appli-
cation of this strategy would be possible, as ATRA is 
a Food and Drug Administration– approved drug to 
treat APL(27) and is currently being clinically trialed 
for treatment of other solid cancers (Clini calTr ials.
gov: NCT04113863).
Hepatology, November 2021LEPORE, CHOY, ET AL.
2578
Acknowledgment: The authors thank Ulf Klein 
(University of Leeds) for the insightful comments to 
the manuscript; Michael B. Yaffe (MIT Center for 
Precision Cancer Medicine) for the GST- PIN1 plas-
mid; J. Zhang (Duke University) for the JNK1CA and 
JNK2CA; G. Franzoso (Imperial College London) for 
the c- Jun and shRNA lentiviral vectors; D. Trono (Ecole 
Polytechnique Federale de Lausanne, Switzerland) for 
the pWPI lentiviral vector; and D. Guardavaccaro 
(University of Verona) for the pWC7- His- Myc- 
Ubiquitin- WT, pCMV- His- HA- Ubiquitin- WT, and 
pWC7- His- Myc- Ubiquitin K0. They also thank L. 
Jary, D. Evans, and J. Bilton (University of Leeds) for 
the technical assistance.
Author Contributions: A.L., P.M.C., N.C.L., M.A.C., 
C.B., and S.P. performed most of the experiments. 
R.F., G.G., and M.L. helped with animal studies and 
data analyses. M.A.B- O. performed quantitative PCR. 
S.S.G. and G.A. provided essential reagents and helped 
with data analyses. C.D’S. performed mass spectrometry 
analyses. A.P. performed the computational modeling 
and interpretation. R.M.T. and W- K.S. helped with data 
analyses and interpretation. C.B. and S.P. are both senior 
and lead authors, conceived the idea, chiefly carried out 
data analysis and interpretation, coordinated and super-
vised the study, obtained research funding, and wrote the 
manuscript, which was commented by all the authors.
ReFeReNCeS
 1) Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 
2014;383:2168- 2179.
 2) Khan SA, Thomas HC, Davidson BR, Taylor- Robinson SD. 
Cholangiocarcinoma. Lancet 2005;366:1303- 1314.
 3) Guest RV, Boulter L, Dwyer BJ, Forbes SJ. Understanding liver 
regeneration to bring new insights to the mechanisms driving 
cholangiocarcinoma. NPJ Regen Med 2017;2:13.
 4) Zou S, li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational 
landscape of intrahepatic cholangiocarcinoma. Nat Commun 
2014;5:5696.
 5) Ikenoue t, terakado y, Nakagawa H, Hikiba Y, Fujii T, 
Matsubara D, et al. A novel mouse model of intrahepatic chol-
angiocarcinoma induced by liver- specific Kras activation and Pten 
deletion. Sci Rep 2016;6:23899.
 6) Robertson S, Hyder O, Dodson R, Nayar SK, Poling J, Beierl K,  
et al. The frequency of KRAS and BRAF mutations in intrahe-
patic cholangiocarcinomas and their correlation with clinical out-
come. Hum Pathol 2013;44:2768- 2773.
 7) Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Köckerling 
F, Hauss J, et al. Frequency of p16(INK4A) alterations and K- ras 
mutations in intrahepatic cholangiocarcinoma of the liver. Gut 
2000;47:721- 727.
 8) Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, et al. 
Kupffer cell- derived Tnf triggers cholangiocellular tumorigenesis 
through JNK due to chronic mitochondrial dysfunction and ROS. 
Cancer Cell 2017;31:771- 789.
 9) Bubici C, Papa S. JNK signalling in cancer: in need of new, 
smarter therapeutic targets. Br J Pharmacol 2014;171:24- 37.
 10) Cellurale C, Sabio g, Kennedy NJ, Das M, Barlow M, Sandy 
P, et al. Requirement of c- Jun NH(2)- terminal kinase for Ras- 
initiated tumor formation. Mol Cell Biol 2011;31:1565- 1576.
 11) Nielsen C, Thastrup J, Bøttzauw T, Jäättelä M, Kallunki T. c- Jun 
NH2- terminal kinase 2 is required for Ras transformation inde-
pendently of activator protein 1. Cancer Res 2007;67:178- 185.
 12) Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in 
regulation of cell function and disease pathogenesis, and clinical 
approaches. Gastroenterology 2012;143:307- 320.
 13) Solinas G, Becattini B. JNK at the crossroad of obesity, insulin 
resistance, and cell stress response. Mol Metab 2016;6:174- 184.
 14) Cubero FJ, Mohamed MR, Woitok MM, Zhao G, Hatting 
M, Nevzorova YA, et al. Loss of c- Jun N- terminal Kinase 1 
and 2 function in liver epithelial cells triggers biliary hyperpro-
liferation resembling cholangiocarcinoma. Hepatol Commun 
2020;4:834- 851.
 15) Manieri E, Folgueira C, Rodríguez ME, Leiva- Vega L, Esteban- 
Lafuente L, Chen C, et al. JNK- mediated disruption of bile acid 
homeostasis promotes intrahepatic cholangiocarcinoma. Proc Natl 
Acad Sci U S A 2020;117:16492- 16499.
 16) Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP. PIN1 is 
an E2F target gene essential for Neu/Ras- induced transformation 
of mammary epithelial cells. Mol Cell Biol 2002;22:5281- 5295.
 17) Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, et al. 
Pin1 is overexpressed in breast cancer and cooperates with Ras 
signaling in increasing the transcriptional activity of c- Jun towards 
cyclin D1. EMBO J 2001;20:3459- 3472.
 18) Wulf G, Garg P, Liou YC, Iglehart D, Lu KP. Modeling breast 
cancer in vivo and ex vivo reveals an essential role of Pin1 in tum-
origenesis. EMBO J 2004;23:3397- 3407.
 19) Lu KP, Hanes SD, Hunter T. A human peptidyl- prolyl isomerase 
essential for regulation of mitosis. Nature 1996;380:544- 547.
 20) Zhou XZ, Lu KP. The isomerase PIN1 controls numerous cancer- 
driving pathways and is a unique drug target. Nat Rev Cancer 
2016;16:463- 478.
 21) Pinch BJ, Doctor ZM, Nabet B, Browne CM, Seo HS, Mohardt 
ML, et al. Identification of a potent and selective covalent Pin1 
inhibitor. Nat Chem Biol 2020;16:979- 987.
 22) Chen Y, Wu YR, Yang HY, Li XZ, Jie MM, Hu CJ, et al. Prolyl 
isomerase Pin1: a promoter of cancer and a target for therapy. Cell 
Death Dis 2018;9:883.
 23) Pu W, Zheng Y, Peng Y. Prolyl isomerase Pin1 in human can-
cer: function, mechanism, and significance. Front Cell Dev Biol 
2020;8:168.
 24) Rustighi A, Zannini A, Campaner E, Ciani Y, Piazza S, Del Sal 
G. PIN1 in breast development and cancer: a clinical perspective. 
Cell Death Differ 2017;24:200- 211.
 25) Jhaveri K, teplinsky e, Silvera D, Valeta- Magara A, Arju R, 
Giashuddin S, et al. Hyperactivated mTOR and JAK2/STAT3 
pathways: molecular drivers and potential therapeutic targets of 
inflammatory and invasive ductal breast cancers after neoadjuvant 
chemotherapy. Clin Breast Cancer 2016;6:113- 122.e1.
 26) Gomez- Chou SB, Swidnicka- Siergiejko AK, Badi N, Chavez- 
Tomar M, Lesinski GB, Bekaii- Saab T, et al. Lipocalin- 2 promotes 
pancreatic ductal adenocarcinoma by regulating inflammation in 
the tumor microenvironment. Cancer Res 2017;77:2647- 2660.
 27) Masetti R, Vendemini F, Zama D, Biagi C, Gasperini P, 
Pession A. All- trans retinoic acid in the treatment of pediat-
ric acute promyelocytic leukemia. Expert Rev Anticancer Ther 
2012;12:1191- 1204.
 28) tong y, ying H, Liu R, Li L, Bergholz J, Xiao ZX. Pin1 inhibits 
PP2A- mediated Rb dephosphorylation in regulation of cell cycle 
and S- phase DNA damage. Cell Death Dis 2015;6:e1640.
Hepatology, Vol. 74, No. 5, 2021 LEPORE, CHOY, ET AL.
2579
 29) Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, 
Franzoso G, et al. Poly(ADP- ribose) polymerase family member 14 
(PARP14) is a novel effector of the JNK2- dependent pro- survival 
signal in multiple myeloma. Oncogene 2013;32:4231- 4242.
 30) Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, et al. 
PARP14 promotes the Warburg effect in hepatocellular carci-
noma by inhibiting JNK1- dependent PKM2 phosphorylation and 
activation. Nat Commun 2015;6:7882.
 31) Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T,  
et al. LMTK3 confers chemo- resistance in breast cancer. 
Oncogene 2018;37:3113- 3130.
 32) Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, et al. 
Serotonin metabolism is dysregulated in cholangiocarcinoma, which 
has implications for tumor growth. Cancer Res 2008;68:9184- 9193.
 33) Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, 
Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N- 
terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681- 13686.
 34) Eckerdt F, Yuan J, Saxena K, Martin B, Kappel S, Lindenau C, 
et al. Polo- like kinase 1- mediated phosphorylation stabilizes 
Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem 
2005;280:36575- 36583.
 35) Basu A, Das M, Qanungo S, Fan XJ, DuBois G, Haldar S. 
Proteasomal degradation of human peptidyl prolyl isomerase 
pin1- pointing phospho Bcl2 toward dephosphorylation. Neoplasia 
2002;4:218- 227.
 36) Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, et al. 
Active Pin1 is a key target of all- trans retinoic acid in acute pro-
myelocytic leukemia and breast cancer. Nat Med 2015;21:457- 466.
 37) Swatek KN, Komander D. Ubiquitin modifications. Cell Res 
2016;26:399- 422.
 38) yuniati l, lauriola a, Gerritsen M, Abreu S, Ni E, Tesoriero C, 
et al. Ubiquitylation of the ER- shaping protein Lunapark via the 
CRL3KLHL12 ubiquitin ligase complex. Cell Rep 2020;31:107664.
 39) Kinoshita E, Kinoshita- Kikuta E, Koike T. Separation and detec-
tion of large phosphoproteins using Phos- tag SDS- PAGE. Nat 
Protoc 2009;4:1513- 1521.
 40) Zeke A, Misheva M, Reményi A, Bogoyevitch MA. JNK signal-
ing: regulation and functions based on complex protein- protein 
partnerships. Microbiol Mol Biol Rev 2016;80:793- 835.
 41) Rangasamy V, Mishra R, Sondarva G, Das S, Lee TH, Bakowska 
JC, et al. Mixed- lineage kinase 3 phosphorylates prolyl- isomerase 
Pin1 to regulate its nuclear translocation and cellular function. 
Proc Natl Acad Sci U S A 2012;109:8149- 8154.
 42) Zhou y, liu S, Song J, Zhang Z. Structural propensities of 
human ubiquitination sites: accessibility, centrality and local con-
formation. PLoS One 2013;8:e83167.
 43) Catic A, Collins C, Church GM, Ploegh HL. Preferred in vivo 
ubiquitination sites. Bioinformatics 2004;20:3302- 3307.
 44) Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and 
functional analysis of the mitotic rotamase Pin1 suggests 
substrate recognition is phosphorylation dependent. Cell 
1997;89:875- 886.
 45) yin Dl, liang yJ, Zheng tS, Song Rp, Wang JB, Sun BS, et al. 
EF24 inhibits tumor growth and metastasis via suppressing NF- 
kappaB dependent pathways in human cholangiocarcinoma. Sci 
Rep 2016;6:32167.
 46) Messoussi A, Feneyrolles C, Bros A, Deroide A, Daydé- Cazals B, 
Chevé G, et al. Recent progress in the design, study, and develop-
ment of c- Jun N- terminal kinase inhibitors as anticancer agents. 
Chem Biol 2014;21:1433- 1443.
 47) Shabek N, Herman- Bachinsky y, Buchsbaum S, Lewinson O, 
Haj- Yahya M, Hejjaoui M, et al. The size of the proteasomal 
substrate determines whether its degradation will be mediated by 
mono- or polyubiquitylation. Mol Cell 2012;48:87- 97.
Author names in bold designate shared co- first authorship.
Supporting Information
Additional Supporting Information may be found at 
onlinelibrary.wiley.com/doi/10.1002/hep.31983/suppinfo.
